Mayne Pharma has identified the following issues most material to its business for sustainability reporting.
Material issues are those that impact the business in terms of growth, cost or risk and are important to stakeholders such as investors, consumers, customers, suppliers, governments and our employees.
Employee health and safety
Ensuring our employees work in a safe environment, which meets or exceeds relevant regulatory expectations, addresses health and safety concerns as they arise and mitigates the risk of reoccurrence of incidents.
Product quality and safety
Choosing materials from quality sources, complying with current Good Manufacturing Practice, and delivering safe products to customers. Mayne Pharma aims to adhere to or exceed strict regulatory standards in all jurisdictions that it serves, and investigates all concerns to ensure our products maintain the highest quality.
Ethical purchasing and human rights in the supply chain
Responsibility to partners to ensure our product line is free from human rights concerns such as forced labour and trafficking, unsafe labour standards and unfair treatment. These issues can arise wherever human resources are utilised across the supply chain.
Corruption and bribery
Business must be conducted with transparency, and free from unethical persuasion. Ethical business practices relate to every aspect of Mayne Pharma’s business, from identifying product sources, through development of pharmaceuticals, transactions with regulatory bodies and sale to customers.
Responsibility to drive compliance with legal and regulatory requirements applicable to our global business. Includes development of policies and controls, communication and training, oversight and continuous improvement and striving for best-practice. Consequently, compliance affects every aspect of what we do, to deliver quality products to consumers.
Resource use and waste management
Includes energy usage during manufacture and logistics, water usage and waste as a by-product of manufacture. Stakeholders increasingly demand disclosure of resource usage and waste management for a more sustainable product investment.
Product pricing and accessibility
Strategies and initiatives designed to provide more affordable pharmaceutical pricing and accessibility to products for patients through development, manufacture and marketing of high-quality generic and branded products.